Chetasi Talati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chetasi Talati has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
Eric Padron
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
8 shared publications- Eric Padron
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
8 shared publications - Andrew Kuykendall
Moffitt Cancer Center, Tampa, USA
7 shared publications - David A. Sallman
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 shared publications Kendra Sweet
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
6 shared publicationsNajla Al Ali
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, USA
6 shared publications
Latest Publications
- Open Access
- 1 February 2022
- Published by Springer Nature in Blood Cancer Journal
- Vol. 12  (2) , 1-6
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
The current World Health Organization (WHO) classification of myeloid malignancies includes myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) as a distinct entity. Previous literature on predictors of survival was based on the provisional category of refractory anemia with ring sideroblast and thrombocytosis (RARS-T), which was not subject to MDS/MPN-RS-T exclusionary criteria such as PB blast% ≥1, BM blast% ≥5 or cytogenetic abnormalities such as t(3;3)(q21.2;q26.2), inv(3)(q21.23q26.2) or isolated del(5q). We examined overall (OS) and leukemia-free (LFS) survival and its predictors, among 158 patients with WHO-defined MDS/MPN-RS-T. In univariate analysis, age ≥70 years (P = 0.006), hemoglobin (Hb) ≤10 g/dL (P = 0.03) and abnormal karyotype (excluding -Y, P = 0.008) were associated with shortened OS, which was otherwise not affected by either ASXL1 (P = 0.7), SF3B1 (P = 0.4) or JAK2 V617F (P = 0.7) mutations; in multivariable analysis, Hb ≤ 10 g/dL (P = 0.03) and abnormal karyotype (P = 0.001) remained significant, and thus allowed the development of an operational survival model with low (0 risk factors, median OS 10.5 years), intermediate (1 risk factor, median OS 4.8 years) and high risk (2 risk factors, median OS 1.4 years) categories (P = 0.0009). Comparison of MDS/MPN-RS-T (n = 158) and MDS/MPN-U with BM RS ≥ 15% (MDS/MPN-U-RS; n = 25) did not reveal significant differences in frequency of thrombosis, OS, or LFS, although SF3B1 mutation frequency was higher in the former (93% versus 59%; P = 0.0005). These data suggest limited survival impact for molecular abnormalities and the morphological distinction between MDS/MPN-RS-T and MDS/MPN-U-RS.
- 1 February 2022
- Published by Springer Nature in Blood Cancer Journal
- Vol. 12  (2) , 1-6
Open AccessMyelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
The current World Health Organization (WHO) classification of myeloid malignancies includes myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) as a distinct entity. Previous literature on predictors of survival was based on the provisional category of refractory anemia with ring sideroblast and thrombocytosis (RARS-T), which was not subject to MDS/MPN-RS-T exclusionary criteria such as PB blast% ≥1, BM blast% ≥5 or cytogenetic abnormalities such as t(3;3)(q21.2;q26.2), inv(3)(q21.23q26.2) or isolated del(5q). We examined overall (OS) and leukemia-free (LFS) survival and its predictors, among 158 patients with WHO-defined MDS/MPN-RS-T. In univariate analysis, age ≥70 years (P = 0.006), hemoglobin (Hb) ≤10 g/dL (P = 0.03) and abnormal karyotype (excluding -Y, P = 0.008) were associated with shortened OS, which was otherwise not affected by either ASXL1 (P = 0.7), SF3B1 (P = 0.4) or JAK2 V617F (P = 0.7) mutations; in multivariable analysis, Hb ≤ 10 g/dL (P = 0.03) and abnormal karyotype (P = 0.001) remained significant, and thus allowed the development of an operational survival model with low (0 risk factors, median OS 10.5 years), intermediate (1 risk factor, median OS 4.8 years) and high risk (2 risk factors, median OS 1.4 years) categories (P = 0.0009). Comparison of MDS/MPN-RS-T (n = 158) and MDS/MPN-U with BM RS ≥ 15% (MDS/MPN-U-RS; n = 25) did not reveal significant differences in frequency of thrombosis, OS, or LFS, although SF3B1 mutation frequency was higher in the former (93% versus 59%; P = 0.0005). These data suggest limited survival impact for molecular abnormalities and the morphological distinction between MDS/MPN-RS-T and MDS/MPN-U-RS.
- 3 January 2022
- Published by Springer Nature in Leukemia
- Vol. 36  (4) , 1189-1192
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts
- 3 January 2022
- Published by Springer Nature in Leukemia
- Vol. 36  (4) , 1189-1192
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts
- Open Access
- 10 October 2021
- Published by Scientific Archives
- Vol. 2  (3)
Moving the Treatment of Acute Myeloid Leukemia to the Outpatient Setting: Current Expert Perspectives and Consensus Findings
- 10 October 2021
- Published by Scientific Archives
- Vol. 2  (3)
Open AccessMoving the Treatment of Acute Myeloid Leukemia to the Outpatient Setting: Current Expert Perspectives and Consensus Findings
- 1 September 2021
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S214
Poster: AML-407: Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes Even in Patients with NPM1 Mutated ELN Favorable Risk AML
- 1 September 2021
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S214
Poster: AML-407: Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes Even in Patients with NPM1 Mutated ELN Favorable Risk AML
- 1 September 2021
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S212
Poster: AML-170: High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients
- 1 September 2021
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S212
Poster: AML-170: High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients
- 18 August 2021
- Published by Wiley in European Journal of Haematology
- Vol. 107  (6) , 609-616
Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes
Objectives The presence of targeted therapy, Enasidenib, for IDH2-mutated AML underscores the importance of understanding the clonal dynamics of IDH2 mutations, which has not been elucidated. In the largest study of IDH2 clonal dynamics, we detail the IDH2-evolutionary patterns and their clinical significance. Methods We analyzed ~6000 patients with NGS results to identify 120 AML patients with IDH2 mutations and longitudinal NGS testing. IDH2 mutation status was recorded at diagnosis, remission, relapse, and persistent disease. Results One hundred and five patients were IDH2-positive at the initial diagnosis, and 15 acquired the mutation later. Of those 15 patients, 7 patients gained the mutation during persistent disease, 6 during relapse, and 2 at remission. Twenty-one patients (18%) who were IDH2-positive in a prior test remained IDH2-positive in remission. Twenty-four patients with IDH2-positive AML were IDH2-positive at relapse. IDH2-positive at diagnosis had better survival than IDH2 mutation acquired later in disease (P = .024). Patients who were IDH2-negative in remission had significantly improved survival (P = .002). Also, loss-of-IDH2 mutation with persistent disease had better OS (P = .035). Conclusions There are 70% that clear IDH2 in disease remission. 12% gain IDH2 mutation later, usually in the setting of refractory/relapsed AML. These patients fared worse. Longitudinal IDH2 testing may be helpful in prognostic stratification.
- 18 August 2021
- Published by Wiley in European Journal of Haematology
- Vol. 107  (6) , 609-616
Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes
Objectives The presence of targeted therapy, Enasidenib, for IDH2-mutated AML underscores the importance of understanding the clonal dynamics of IDH2 mutations, which has not been elucidated. In the largest study of IDH2 clonal dynamics, we detail the IDH2-evolutionary patterns and their clinical significance. Methods We analyzed ~6000 patients with NGS results to identify 120 AML patients with IDH2 mutations and longitudinal NGS testing. IDH2 mutation status was recorded at diagnosis, remission, relapse, and persistent disease. Results One hundred and five patients were IDH2-positive at the initial diagnosis, and 15 acquired the mutation later. Of those 15 patients, 7 patients gained the mutation during persistent disease, 6 during relapse, and 2 at remission. Twenty-one patients (18%) who were IDH2-positive in a prior test remained IDH2-positive in remission. Twenty-four patients with IDH2-positive AML were IDH2-positive at relapse. IDH2-positive at diagnosis had better survival than IDH2 mutation acquired later in disease (P = .024). Patients who were IDH2-negative in remission had significantly improved survival (P = .002). Also, loss-of-IDH2 mutation with persistent disease had better OS (P = .035). Conclusions There are 70% that clear IDH2 in disease remission. 12% gain IDH2 mutation later, usually in the setting of refractory/relapsed AML. These patients fared worse. Longitudinal IDH2 testing may be helpful in prognostic stratification.
- 30 April 2021
- Published by Springer Nature in Leukemia
- Vol. 35  (11) , 3329-3333
Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted
- 30 April 2021
- Published by Springer Nature in Leukemia
- Vol. 35  (11) , 3329-3333
Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted
- 1 November 2020
- Published by Springer Nature in Leukemia
- Vol. 35  (1) , 286-288
PTPN11 mutations are associated with poor outcomes across myeloid malignancies
- 1 November 2020
- Published by Springer Nature in Leukemia
- Vol. 35  (1) , 286-288
PTPN11 mutations are associated with poor outcomes across myeloid malignancies
- 1 June 2020
- Published by Elsevier in Leukemia Research
- Vol. 93, 106367
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
- 1 June 2020
- Published by Elsevier in Leukemia Research
- Vol. 93, 106367
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy